
Annual report 2025
added 02-24-2026
Avanos Medical EBITDA 2011-2026 | AVNS
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Avanos Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.7 M | -351 M | 50.3 M | 83.2 M | 48.7 M | -5.6 M | -18.8 M | 34 M | 16.4 M | 153 M | 162 M | 180 M | 294 M | 286 M | 262 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 294 M | -351 M | 78 M |
Quarterly EBITDA Avanos Medical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.1 M | -69.7 M | 19.9 M | - | 17.3 M | 11.3 M | 15.4 M | - | 6 M | 2.4 M | 6 M | - | 17.3 M | 14.5 M | 19.7 M | - | 32.2 M | 11.9 M | -2.7 M | - | 32 M | 19.6 M | 11.2 M | - | 7.5 M | 7.1 M | -16.2 M | - | 31.5 M | 24.4 M | 800 K | - | 38.1 M | 20.3 M | -1.4 M | - | 69.3 M | 49.4 M | 48.7 M | - | -413 M | 54.4 M | 57.3 M | - | 74.7 M | 30.3 M | 79 M | - | 123 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 123 M | -413 M | 12.3 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
753 M | $ 185.57 | 2.71 % | $ 13.9 B | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | ||
|
AxoGen
AXGN
|
-1.19 M | $ 34.13 | 1.97 % | $ 1.57 B | ||
|
BioSig Technologies
BSGM
|
-67.6 M | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
473 M | $ 12.71 | 3.17 % | $ 1.72 B | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
421 M | $ 291.68 | 1.22 % | $ 8.23 B | ||
|
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 0.58 | -0.87 % | $ 36.1 M | ||
|
IRIDEX Corporation
IRIX
|
-2.05 M | $ 1.03 | 0.49 % | $ 17.4 M | ||
|
EDAP TMS S.A.
EDAP
|
-18 M | $ 3.22 | -3.23 % | $ 121 M | ||
|
Bruker Corporation
BRKR
|
437 M | $ 39.91 | 2.2 % | $ 5.95 K | ||
|
Boston Scientific Corporation
BSX
|
4.98 B | $ 64.04 | 1.36 % | $ 94.8 B | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
LENSAR
LNSR
|
-21 M | $ 6.03 | 1.86 % | $ 72.1 M | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
ClearPoint Neuro
CLPT
|
-23.4 M | $ 10.29 | 2.8 % | $ 291 M | ||
|
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | ||
|
Second Sight Medical Products
EYES
|
-27.1 M | - | -0.97 % | $ 54.4 M | ||
|
Myomo
MYO
|
-13.5 M | $ 0.77 | 5.27 % | $ 32.2 M | ||
|
Electromed
ELMD
|
10.7 M | $ 25.41 | 1.84 % | $ 215 M | ||
|
Inogen
INGN
|
-9.55 M | $ 6.36 | -1.4 % | $ 169 M | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
Sintx Technologies
SINT
|
-10.4 M | $ 2.85 | -3.06 % | $ 7.9 M | ||
|
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
Globus Medical
GMED
|
757 M | $ 95.44 | 2.65 % | $ 12.9 B | ||
|
Stryker Corporation
SYK
|
6.46 B | $ 347.71 | 0.14 % | $ 133 B | ||
|
Tactile Systems Technology
TCMD
|
35.9 M | $ 24.58 | 1.38 % | $ 562 M | ||
|
Helius Medical Technologies
HSDT
|
-12.4 M | $ 1.97 | -2.96 % | $ 1.2 M | ||
|
Butterfly Network
BFLY
|
-65.5 M | $ 4.39 | 2.57 % | $ 929 M | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
TransMedics Group
TMDX
|
136 M | $ 115.53 | 1.91 % | $ 3.93 B | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
Tandem Diabetes Care
TNDM
|
26 M | $ 20.79 | 3.45 % | $ 1.41 B | ||
|
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 17.7 | 4.42 % | $ 415 M | ||
|
Delcath Systems
DCTH
|
898 K | $ 10.74 | 2.78 % | $ 385 M | ||
|
Inspire Medical Systems
INSP
|
64.9 M | $ 55.81 | 1.62 % | $ 1.64 B | ||
|
CONMED Corporation
CNMD
|
120 M | $ 39.41 | 2.47 % | $ 1.22 B |